Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Michael H. Davidson to Risk Factors

This is a "connection" page, showing publications Michael H. Davidson has written about Risk Factors.

 
Connection Strength
 
 
 
3.743
 
  1. Pulipati VP, Davidson MH. Recent advances and emerging therapies in management of dyslipidemias. Trends Cardiovasc Med. 2021 10; 31(7):419-424.
    View in: PubMed
    Score: 0.096
  2. Davidson M, Wagner AD, Kouvelakis K, Nanji H, Starling N, Chau I, Watkins D, Rao S, Peckitt C, Cunningham D. Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: A pooled analysis of four randomised trials. Eur J Cancer. 2019 11; 121:40-47.
    View in: PubMed
    Score: 0.090
  3. Benes LB, Brummell K, Roth M, Shen L, Davidson MH. The Role of Genetics in Cardiovascular Risk Reduction: Findings From a Single Lipid Clinic and Review of the Literature. Cardiovasc Revasc Med. 2020 02; 21(2):200-204.
    View in: PubMed
    Score: 0.088
  4. White WB, Kloner RA, Angiolillo DJ, Davidson MH. Cardiorenal Safety of OTC Analgesics. J Cardiovasc Pharmacol Ther. 2018 03; 23(2):103-118.
    View in: PubMed
    Score: 0.081
  5. Benes LB, Bassi NS, Davidson MH. Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia. Vasc Health Risk Manag. 2016; 12:481-490.
    View in: PubMed
    Score: 0.074
  6. Davidson DJ, Davidson MH. Using Discordance in Monozygotic Twins to Understand Causality of Cardiovascular Disease Risk Factors. JAMA Intern Med. 2016 10 01; 176(10):1530.
    View in: PubMed
    Score: 0.073
  7. Benes LB, Bassi NS, Davidson MH. The Risk of Hepatotoxicity, New Onset Diabetes and Rhabdomyolysis in the Era of High-Intensity Statin Therapy: Does Statin Type Matter? Prog Cardiovasc Dis. 2016 Sep - Oct; 59(2):145-152.
    View in: PubMed
    Score: 0.073
  8. Smith BA, Wright C, Davidson M. Role of Ezetimibe in Lipid-Lowering and Cardiovascular Disease Prevention. Curr Atheroscler Rep. 2015 Dec; 17(12):72.
    View in: PubMed
    Score: 0.069
  9. Davidson MH, Tomassini JE, Jensen E, Neff D, Polis AB, Tershakovec AM. Changing characteristics of statin-related cIMT trials from 1988 to 2006. Atherosclerosis. 2016 Mar; 246:121-9.
    View in: PubMed
    Score: 0.069
  10. Davidson MH. Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus. Postgrad Med. 2014 May; 126(3):56-65.
    View in: PubMed
    Score: 0.062
  11. Wilkinson MJ, Laffin LJ, Davidson MH. Overcoming toxicity and side-effects of lipid-lowering therapies. Best Pract Res Clin Endocrinol Metab. 2014 Jun; 28(3):439-52.
    View in: PubMed
    Score: 0.061
  12. Thomas GS, Cromwell WC, Ali S, Chin W, Flaim JD, Davidson M. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2013 Dec 10; 62(23):2178-84.
    View in: PubMed
    Score: 0.059
  13. Maki KC, Orloff DG, Nicholls SJ, Dunbar RL, Roth EM, Curcio D, Johnson J, Kling D, Davidson MH. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). Clin Ther. 2013 Sep; 35(9):1400-11.e1-3.
    View in: PubMed
    Score: 0.059
  14. Davidson MH. Cardiovascular risk factors in a patient with diabetes mellitus and coronary artery disease: therapeutic approaches to improve outcomes: perspectives of a preventive cardiologist. Am J Cardiol. 2012 Nov 06; 110(9 Suppl):43B-49B.
    View in: PubMed
    Score: 0.056
  15. Davidson M, Rosenson RS, Maki KC, Nicholls SJ, Ballantyne CM, Setze C, Carlson DM, Stolzenbach J. Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. Cardiovasc Drugs Ther. 2012 Aug; 26(4):349-58.
    View in: PubMed
    Score: 0.055
  16. Cziraky MJ, Willey VJ, McKenney JM, Kamat SA, Fisher MD, Guyton JR, Jacobson TA, Davidson MH. Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. J Clin Lipidol. 2013 Mar-Apr; 7(2):102-8.
    View in: PubMed
    Score: 0.055
  17. Mangalmurti SS, Davidson MH. The incremental value of lipids and inflammatory biomarkers in determining residual cardiovascular risk. Curr Atheroscler Rep. 2011 Oct; 13(5):373-80.
    View in: PubMed
    Score: 0.052
  18. Davidson MH. Pharmacotherapy: Implications of high-dose statin link with incident diabetes. Nat Rev Cardiol. 2011 Aug 02; 8(10):543-4.
    View in: PubMed
    Score: 0.051
  19. Davidson MH. Focusing on high-density lipoprotein for coronary heart disease risk reduction. Cardiol Clin. 2011 Feb; 29(1):105-22.
    View in: PubMed
    Score: 0.049
  20. Weiser M, Werbeloff N, Levine A, Livni G, Schreiber S, Halperin D, Yoffe R, Davidson M. CNS infection in childhood does not confer risk for later schizophrenia: a case-control study. Schizophr Res. 2010 Dec; 124(1-3):231-5.
    View in: PubMed
    Score: 0.048
  21. Davidson MH, Beam CA, Haffner S, Perez A, D'Agostino R, Mazzone T. Pioglitazone versus glimepiride on coronary artery calcium progression in patients with type 2 diabetes mellitus: a secondary end point of the CHICAGO study. Arterioscler Thromb Vasc Biol. 2010 Sep; 30(9):1873-6.
    View in: PubMed
    Score: 0.047
  22. Davidson MH. Counterpoint: Low-density lipoprotein cholesterol goals in patients with diabetes are adequately based on evidence. J Clin Lipidol. 2010 Jan-Feb; 4(1):72-3; discussion 74.
    View in: PubMed
    Score: 0.046
  23. Braun LT, Davidson MH. Lp-PLA2: A new target for statin therapy. Curr Atheroscler Rep. 2010 Jan; 12(1):29-33.
    View in: PubMed
    Score: 0.046
  24. Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. Clin Ther. 2009 Dec; 31(12):2824-38.
    View in: PubMed
    Score: 0.046
  25. Davidson MH. Apolipoprotein measurements: is more widespread use clinically indicated? Clin Cardiol. 2009 Sep; 32(9):482-6.
    View in: PubMed
    Score: 0.045
  26. Dembowski E, Davidson MH. A review of lipid management in primary and secondary prevention. J Cardiopulm Rehabil Prev. 2009 Jan-Feb; 29(1):2-12.
    View in: PubMed
    Score: 0.043
  27. Borden WB, Davidson MH. Updating the assessment of cardiac risk: beyond Framingham. Rev Cardiovasc Med. 2009; 10(2):63-71.
    View in: PubMed
    Score: 0.043
  28. Davidson M. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome. Am J Cardiol. 2008 Dec 22; 102(12A):19L-27L.
    View in: PubMed
    Score: 0.043
  29. Dembowski E, Davidson MH. Should every patient with diabetes receive a statin? Pol Arch Med Wewn. 2008 Jul-Aug; 118(7-8):398-401.
    View in: PubMed
    Score: 0.041
  30. Davidson MH. Introduction. U.S. incidence of coronary artery disease. Am J Cardiol. 2008 Jun 16; 101(12A):1F-2F.
    View in: PubMed
    Score: 0.041
  31. Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol. 2008 Jun 16; 101(12A):41F-50F.
    View in: PubMed
    Score: 0.041
  32. Davidson MH, Corson MA, Alberts MJ, Anderson JL, Gorelick PB, Jones PH, Lerman A, McConnell JP, Weintraub HS. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol. 2008 Jun 16; 101(12A):51F-57F.
    View in: PubMed
    Score: 0.041
  33. Toth PP, Davidson MH. High-dose statin therapy: benefits and safety in aggressive lipid lowering. J Fam Pract. 2008 May; 57(5 Suppl High-Dose):S29-36.
    View in: PubMed
    Score: 0.041
  34. Davidson MH. Niacin use and cutaneous flushing: mechanisms and strategies for prevention. Am J Cardiol. 2008 Apr 17; 101(8A):14B-19B.
    View in: PubMed
    Score: 0.041
  35. Polonsky TS, Davidson MH. Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy. Am J Cardiol. 2008 Apr 17; 101(8A):27B-35B.
    View in: PubMed
    Score: 0.041
  36. Davidson M, Meyer PM, Haffner S, Feinstein S, D'Agostino R, Kondos GT, Perez A, Chen Z, Mazzone T. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation. 2008 Apr 22; 117(16):2123-30.
    View in: PubMed
    Score: 0.041
  37. Stein JH, Tzou WS, DeCara JM, Hirsch AT, Mohler ER, Ouyang P, Pearce GL, Davidson MH. Usefulness of increased skin cholesterol to identify individuals at increased cardiovascular risk (from the Predictor of Advanced Subclinical Atherosclerosis study). Am J Cardiol. 2008 Apr 01; 101(7):986-91.
    View in: PubMed
    Score: 0.040
  38. Davidson MH. Overview of prevention and treatment of atherosclerosis with lipid-altering therapy for pharmacy directors. Am J Manag Care. 2007 Dec; 13 Suppl 10:S260-9.
    View in: PubMed
    Score: 0.040
  39. Fox KM, Gandhi SK, Ohsfeldt RL, Blasetto JW, Davidson MH. Effectiveness of statins in Medicare-eligible patients and patients < 65 years using clinical practice data. Int J Clin Pract. 2007 Oct; 61(10):1634-42.
    View in: PubMed
    Score: 0.039
  40. Kamat SA, Gandhi SK, Davidson M. Comparative effectiveness of rosuvastatin versus other statin therapies in patients at increased risk of failure to achieve low-density lipoprotein goals. Curr Med Res Opin. 2007 May; 23(5):1121-30.
    View in: PubMed
    Score: 0.038
  41. Goldbourt U, Schnaider-Beeri M, Davidson M. Socioeconomic status in relationship to death of vascular disease and late-life dementia. J Neurol Sci. 2007 Jun 15; 257(1-2):177-81.
    View in: PubMed
    Score: 0.038
  42. Maki KC, Rains TM, Kaden VN, Raneri KR, Davidson MH. Effects of a reduced-glycemic-load diet on body weight, body composition, and cardiovascular disease risk markers in overweight and obese adults. Am J Clin Nutr. 2007 Mar; 85(3):724-34.
    View in: PubMed
    Score: 0.038
  43. Davidson MH, Basile J, Garber AJ, Phillips RA. Reducing the risk of stroke through appropriate targets and treatments. Prev Cardiol. 2007; 10(4):215-21.
    View in: PubMed
    Score: 0.037
  44. Davidson MH. Global risk management in patients with type 2 diabetes mellitus. Am J Cardiol. 2007 Feb 19; 99(4A):41B-50B.
    View in: PubMed
    Score: 0.037
  45. Davidson M, Zhu J, Lu W, Tracy RP, Robbins DC, Resnick HE, Ruotolo G, Howard BV. Plasminogen activator inhibitor-1 and the risk of Type 2 diabetes mellitus in American Indians: the Strong Heart Study. Diabet Med. 2006 Oct; 23(10):1158-9.
    View in: PubMed
    Score: 0.037
  46. Robinson JG, Davidson MH. How low to target LDL? Nat Clin Pract Endocrinol Metab. 2006 Aug; 2(8):414-5.
    View in: PubMed
    Score: 0.036
  47. Reichenberg A, Weiser M, Rapp MA, Rabinowitz J, Caspi A, Schmeidler J, Knobler HY, Lubin G, Nahon D, Harvey PD, Davidson M. Premorbid intra-individual variability in intellectual performance and risk for schizophrenia: a population-based study. Schizophr Res. 2006 Jul; 85(1-3):49-57.
    View in: PubMed
    Score: 0.036
  48. Reichenberg A, Weiser M, Caspi A, Knobler HY, Lubin G, Harvey PD, Rabinowitz J, Davidson M. Premorbid intellectual functioning and risk of schizophrenia and spectrum disorders. J Clin Exp Neuropsychol. 2006 Feb; 28(2):193-207.
    View in: PubMed
    Score: 0.035
  49. Davidson MH. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf. 2006 Jan; 5(1):145-56.
    View in: PubMed
    Score: 0.035
  50. Deedwania PC, Maki KC, Dicklin MR, Stone NJ, Ballantyne CM, Davidson MH. Application of recent definitions of the metabolic syndrome to survey data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II). J Cardiometab Syndr. 2006; 1(5):295-300.
    View in: PubMed
    Score: 0.035
  51. Reichenberg A, Weiser M, Rapp MA, Rabinowitz J, Caspi A, Schmeidler J, Knobler HY, Lubin G, Nahon D, Harvey PD, Davidson M. Elaboration on premorbid intellectual performance in schizophrenia: premorbid intellectual decline and risk for schizophrenia. Arch Gen Psychiatry. 2005 Dec; 62(12):1297-304.
    View in: PubMed
    Score: 0.035
  52. Corsini A, Bellosta S, Davidson MH. Pharmacokinetic interactions between statins and fibrates. Am J Cardiol. 2005 Nov 07; 96(9A):44K-49K; discussion 34K-35K.
    View in: PubMed
    Score: 0.034
  53. Maki KC, Galant R, Davidson MH. Non-high-density lipoprotein cholesterol: the forgotten therapeutic target. Am J Cardiol. 2005 Nov 07; 96(9A):59K-64K; discussion 34K-35K.
    View in: PubMed
    Score: 0.034
  54. Davidson MH. Reducing residual risk for patients on statin therapy: the potential role of combination therapy. Am J Cardiol. 2005 Nov 07; 96(9A):3K-13K; discussion 34K-35K.
    View in: PubMed
    Score: 0.034
  55. Davidson MH, Maki KC, Pearson TA, Pasternak RC, Deedwania PC, McKenney JM, Fonarow GC, Maron DJ, Ansell BJ, Clark LT, Ballantyne CM. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005 Aug 15; 96(4):556-63.
    View in: PubMed
    Score: 0.034
  56. Schnaider Beeri M, Goldbourt U, Silverman JM, Noy S, Schmeidler J, Ravona-Springer R, Sverdlick A, Davidson M. Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology. 2004 Nov 23; 63(10):1902-7.
    View in: PubMed
    Score: 0.032
  57. Davidson MH. Reducing cardiovascular risk: trends in risk, risk assessment, and cholesterol management. Postgrad Med. 2004 Sep; 116(3 Suppl):7-12.
    View in: PubMed
    Score: 0.032
  58. Weiser M, Reichenberg A, Grotto I, Yasvitzky R, Rabinowitz J, Lubin G, Nahon D, Knobler HY, Davidson M. Higher rates of cigarette smoking in male adolescents before the onset of schizophrenia: a historical-prospective cohort study. Am J Psychiatry. 2004 Jul; 161(7):1219-23.
    View in: PubMed
    Score: 0.031
  59. Davidson MH. A look to the future: new treatment guidelines and a perspective on statins. Am J Med. 2002 Jun 03; 112 Suppl 8A:34S-41S.
    View in: PubMed
    Score: 0.027
  60. Davidson M, Min YI, Holbrook JT, Van Natta ML, Murphy R, Jabs DA, Welch W, Meinert CL. Use of filgrastim as adjuvant therapy in patients with AIDS-related cytomegalovirus retinitis. AIDS. 2002 Mar 29; 16(5):757-65.
    View in: PubMed
    Score: 0.027
  61. Davidson MH. Strategies to improve Adult Treatment Panel III guideline adherence and patient compliance. Am J Cardiol. 2002 Mar 07; 89(5A):8C-20C; discussion 20C-22C.
    View in: PubMed
    Score: 0.027
  62. Davidson M. Risk of cardiovascular disease and sudden death in schizophrenia. J Clin Psychiatry. 2002; 63 Suppl 9:5-11.
    View in: PubMed
    Score: 0.026
  63. Weiser M, Reichenberg A, Rabinowitz J, Kaplan Z, Mark M, Bodner E, Nahon D, Davidson M. Association between nonpsychotic psychiatric diagnoses in adolescent males and subsequent onset of schizophrenia. Arch Gen Psychiatry. 2001 Oct; 58(10):959-64.
    View in: PubMed
    Score: 0.026
  64. Davidson MH. Treatment of the elderly with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: focus on drug interactions. J Cardiovasc Pharmacol Ther. 2001 Jul; 6(3):219-29.
    View in: PubMed
    Score: 0.025
  65. Davidson MH, Maki KC, Marx P, Maki AC, Cyrowski MS, Nanavati N, Arce JC. Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women. Arch Intern Med. 2000 Nov 27; 160(21):3315-25.
    View in: PubMed
    Score: 0.024
  66. Handelsman Y, Jellinger PS, Guerin CK, Bloomgarden ZT, Brinton EA, Budoff MJ, Davidson MH, Einhorn D, Fazio S, Fonseca VA, Garber AJ, Grunberger G, Krauss RM, Mechanick JI, Rosenblit PD, Smith DA, Wyne KL. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary. Endocr Pract. 2020 Oct; 26(10):1196-1224.
    View in: PubMed
    Score: 0.024
  67. Moriarty PM, Gorby LK, Stroes ES, Kastelein JP, Davidson M, Tsimikas S. Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis. Curr Atheroscler Rep. 2020 07 25; 22(9):48.
    View in: PubMed
    Score: 0.024
  68. Davidson MH. Does differing metabolism by cytochrome p450 have clinical importance? Curr Atheroscler Rep. 2000 Jan; 2(1):14-9.
    View in: PubMed
    Score: 0.023
  69. Vallejo-Vaz AJ, Ray KK, Ginsberg HN, Davidson MH, Eckel RH, Lee LV, Bessac L, Pordy R, Letierce A, Cannon CP. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. Atherosclerosis. 2019 09; 288:85-93.
    View in: PubMed
    Score: 0.022
  70. Ray KK, Vallejo-Vaz AJ, Ginsberg HN, Davidson MH, Louie MJ, Bujas-Bobanovic M, Minini P, Eckel RH, Cannon CP. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. Atherosclerosis. 2019 09; 288:194-202.
    View in: PubMed
    Score: 0.022
  71. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J, Heymsfield SB. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999 Jan 20; 281(3):235-42.
    View in: PubMed
    Score: 0.021
  72. Nicholls SJ, Lincoff AM, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, Mozaffarian D, Pedersen TR, Ridker PM, Ray K, Karlson BW, Lundström T, Wolski K, Nissen SE. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. Clin Cardiol. 2018 Oct; 41(10):1281-1288.
    View in: PubMed
    Score: 0.021
  73. Davidson M, Kuo CC, Middaugh JP, Campbell LA, Wang SP, Newman WP, Finley JC, Grayston JT. Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis. Circulation. 1998 Aug 18; 98(7):628-33.
    View in: PubMed
    Score: 0.021
  74. Analysis of shared heritability in common disorders of the brain. Science. 2018 06 22; 360(6395).
    View in: PubMed
    Score: 0.021
  75. Morton AM, Furtado JD, Lee J, Amerine W, Davidson MH, Sacks FM. The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia. J Clin Lipidol. 2016 Nov - Dec; 10(6):1442-1451.e4.
    View in: PubMed
    Score: 0.018
  76. Weiser M, Goldberg S, Werbeloff N, Fenchel D, Reichenberg A, Shelef L, Large M, Davidson M, Fruchter E. Risk of completed suicide in 89,049 young males assessed by a mental health professional. Eur Neuropsychopharmacol. 2016 Feb; 26(2):341-349.
    View in: PubMed
    Score: 0.017
  77. Sampson UK, Harrell FE, Fazio S, Nwosu S, Mercaldo N, Mensah GA, Davidson MH, Coll B, Feinstein SB. Carotid adventitial vasa vasorum and intima-media thickness in a primary prevention population. Echocardiography. 2015 Feb; 32(2):264-70.
    View in: PubMed
    Score: 0.016
  78. Davidson M, Schnitzer PG, Bulkow LR, Parkinson AJ, Schloss ML, Fitzgerald MA, Knight JA, Murphy CM, Kiviat NB, Toomey KE, et al. The prevalence of cervical infection with human papillomaviruses and cervical dysplasia in Alaska Native women. J Infect Dis. 1994 Apr; 169(4):792-800.
    View in: PubMed
    Score: 0.015
  79. Freed BH, Narang A, Bhave NM, Czobor P, Mor-Avi V, Zaran ER, Turner KM, Cavanaugh KP, Chandra S, Tanaka SM, Davidson MH, Lang RM, Patel AR. Prognostic value of normal regadenoson stress perfusion cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2013 Dec 21; 15:108.
    View in: PubMed
    Score: 0.015
  80. [Official document of the International Society of Atherosclerosis: general recommendations for treatment of dyslipidemia. Executive summary]. Clin Investig Arterioscler. 2014 Jan-Feb; 26(1):33-7.
    View in: PubMed
    Score: 0.015
  81. Gotto AM, Cannon CP, Li XS, Vaidya S, Kher U, Brinton EA, Davidson M, Moon JE, Shah S, Dansky HM, Mitchel Y, Barter P. Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. Am J Cardiol. 2014 Jan 01; 113(1):76-83.
    View in: PubMed
    Score: 0.015
  82. Kaneko T, Aranki S, Javed Q, McGurk S, Shekar P, Davidson M, Cohn L. Mechanical versus bioprosthetic mitral valve replacement in patients <65 years old. J Thorac Cardiovasc Surg. 2014 Jan; 147(1):117-26.
    View in: PubMed
    Score: 0.015
  83. Toth PP, Barter PJ, Rosenson RS, Boden WE, Chapman MJ, Cuchel M, D'Agostino RB, Davidson MH, Davidson WS, Heinecke JW, Karas RH, Kontush A, Krauss RM, Miller M, Rader DJ. High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol. 2013 Sep-Oct; 7(5):484-525.
    View in: PubMed
    Score: 0.015
  84. Ballantyne CM, Davidson MH, Macdougall DE, Bays HE, Dicarlo LA, Rosenberg NL, Margulies J, Newton RS. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013 Sep 24; 62(13):1154-62.
    View in: PubMed
    Score: 0.015
  85. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez G, Davidson MH. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013 Mar-Apr; 19(2):327-36.
    View in: PubMed
    Score: 0.014
  86. Hovingh GK, Davidson MH, Kastelein JJ, O'Connor AM. Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J. 2013 Apr; 34(13):962-71.
    View in: PubMed
    Score: 0.014
  87. Sullivan PF, Magnusson C, Reichenberg A, Boman M, Dalman C, Davidson M, Fruchter E, Hultman CM, Lundberg M, Långström N, Weiser M, Svensson AC, Lichtenstein P. Family history of schizophrenia and bipolar disorder as risk factors for autism. Arch Gen Psychiatry. 2012 Nov; 69(11):1099-1103.
    View in: PubMed
    Score: 0.014
  88. Roth EM, Rosenson RS, Jones PH, Davidson MH, Kelly MT, Setze CM, Lele A, Thakker K. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies. J Clin Lipidol. 2012 Nov-Dec; 6(6):534-44.
    View in: PubMed
    Score: 0.013
  89. Maki KC, Dicklin MR, Davidson MH, Mize PD, Kulkarni KR. Indicators of the atherogenic lipoprotein phenotype measured with density gradient ultracentrifugation predict changes in carotid intima-media thickness in men and women. Vasc Health Risk Manag. 2012; 8:31-8.
    View in: PubMed
    Score: 0.013
  90. Berger JS, Ballantyne CM, Davidson MH, Johnson JL, Tarka EA, Lawrence D, Trivedi T, Zalewski A, Mohler ER. Peripheral artery disease, biomarkers, and darapladib. Am Heart J. 2011 May; 161(5):972-8.
    View in: PubMed
    Score: 0.013
  91. Maki KC, Davidson MH, Dicklin MR, Bell M, Witchger M, Feinstein SB. Predictors of anterior and posterior wall carotid intima media thickness progression in men and women at moderate risk of coronary heart disease. J Clin Lipidol. 2011 May-Jun; 5(3):141-151.
    View in: PubMed
    Score: 0.012
  92. Brown WV, Bays H, Davidson M, Goldberg A. Drugs in development for management of lipoprotein disorders. J Clin Lipidol. 2011 Mar-Apr; 5(2):66-75.
    View in: PubMed
    Score: 0.012
  93. Gilbert J, Lekstrom-Himes J, Donaldson D, Lee Y, Hu M, Xu J, Wyant T, Davidson M. Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region. Am J Cardiol. 2011 Mar 15; 107(6):906-11.
    View in: PubMed
    Score: 0.012
  94. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010 Dec 16; 363(25):2406-15.
    View in: PubMed
    Score: 0.012
  95. Polis AB, Abate N, Catapano AL, Ballantyne CM, Davidson MH, Smugar SS, Tershakovec AM. Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category. Metab Syndr Relat Disord. 2009 Dec; 7(6):601-10.
    View in: PubMed
    Score: 0.011
  96. Maccubbin D, Koren MJ, Davidson M, Gavish D, Pasternak RC, Macdonell G, Mallick M, Sisk CM, Paolini JF, Mitchel Y. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol. 2009 Jul 01; 104(1):74-81.
    View in: PubMed
    Score: 0.011
  97. Friedewald VE, Ballantyne CM, Davidson MH, Guyton JR, Roberts WC. The editor's roundtable: lipid management beyond statins-reducing residual cardiovascular risk. Am J Cardiol. 2008 Sep 01; 102(5):559-67.
    View in: PubMed
    Score: 0.010
  98. Musunuru K, Kral BG, Blumenthal RS, Fuster V, Campbell CY, Gluckman TJ, Lange RA, Topol EJ, Willerson JT, Desai MY, Davidson MH, Mora S. The use of high-sensitivity assays for C-reactive protein in clinical practice. Nat Clin Pract Cardiovasc Med. 2008 Oct; 5(10):621-35.
    View in: PubMed
    Score: 0.010
  99. Beeri MS, Davidson M, Silverman JM, Schmeidler J, Springer RR, Noy S, Goldbourt U. Religious education and midlife observance are associated with dementia three decades later in Israeli men. J Clin Epidemiol. 2008 Nov; 61(11):1161-8.
    View in: PubMed
    Score: 0.010
  100. Skulas-Ray AC, West SG, Davidson MH, Kris-Etherton PM. Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia. Expert Opin Pharmacother. 2008 May; 9(7):1237-48.
    View in: PubMed
    Score: 0.010
  101. Mohler ER, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, Zalewski A. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2008 Apr 29; 51(17):1632-41.
    View in: PubMed
    Score: 0.010
  102. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008 Apr 15; 51(15):1512-24.
    View in: PubMed
    Score: 0.010
  103. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008 Apr; 31(4):811-22.
    View in: PubMed
    Score: 0.010
  104. Brotman DJ, Davidson MB, Boumitri M, Vidt DG. Impaired diurnal blood pressure variation and all-cause mortality. Am J Hypertens. 2008 Jan; 21(1):92-7.
    View in: PubMed
    Score: 0.010
  105. Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis. 2008 Mar; 197(1):12-24.
    View in: PubMed
    Score: 0.010
  106. Brown S, Atkins C, Bagley R, Carr A, Cowgill L, Davidson M, Egner B, Elliott J, Henik R, Labato M, Littman M, Polzin D, Ross L, Snyder P, Stepien R. Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. J Vet Intern Med. 2007 May-Jun; 21(3):542-58.
    View in: PubMed
    Score: 0.010
  107. Mazzone T, Meyer PM, Kondos GT, Davidson MH, Feinstein SB, D'Agostino RB, Perez A, Haffner SM. Relationship of traditional and nontraditional cardiovascular risk factors to coronary artery calcium in type 2 diabetes. Diabetes. 2007 Mar; 56(3):849-55.
    View in: PubMed
    Score: 0.009
  108. Reichenberg A, Gross R, Weiser M, Bresnahan M, Silverman J, Harlap S, Rabinowitz J, Shulman C, Malaspina D, Lubin G, Knobler HY, Davidson M, Susser E. Advancing paternal age and autism. Arch Gen Psychiatry. 2006 Sep; 63(9):1026-32.
    View in: PubMed
    Score: 0.009
  109. McKenney JM, Davidson MH, Saponaro J, Thompson PD, Bays HE. Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin. J Cardiovasc Pharmacol. 2005 Nov; 46(5):594-9.
    View in: PubMed
    Score: 0.009
  110. Best LG, Zhang Y, Lee ET, Yeh JL, Cowan L, Palmieri V, Roman M, Devereux RB, Fabsitz RR, Tracy RP, Robbins D, Davidson M, Ahmed A, Howard BV. C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study. Circulation. 2005 Aug 30; 112(9):1289-95.
    View in: PubMed
    Score: 0.008
  111. Howard BV, Devereux RB, Cole SA, Davidson M, Dyke B, Ebbesson SO, Epstein SE, Robinson DR, Jarvis B, Kaufman DJ, Laston S, MacCluer JW, Okin PM, Roman MJ, Romenesko T, Ruotolo G, Swenson M, Wenger CR, Williams-Blangero S, Zhu J, Saccheus C, Fabsitz RR, Robbins DC. A genetic and epidemiologic study of cardiovascular disease in Alaska natives (GOCADAN): design and methods. Int J Circumpolar Health. 2005 Jun; 64(3):206-21.
    View in: PubMed
    Score: 0.008
  112. Deedwania PC, Davidson MH, Ballantyne CM. Treating dyslipidemia in high-risk patients: case reviews and discussion. Postgrad Med. 2004 Sep; 116(3 Suppl):21-8.
    View in: PubMed
    Score: 0.008
  113. Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M, Lindenmayer JP, Manoukian SV, Banerji MA, Lebovitz HE, Hennekens CH. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004; 65 Suppl 7:4-18; quiz 19-20.
    View in: PubMed
    Score: 0.008
  114. Schumacher C, Davidson M, Ehrsam G. Cardiovascular disease among Alaska Natives: a review of the literature. Int J Circumpolar Health. 2003 Dec; 62(4):343-62.
    View in: PubMed
    Score: 0.008
  115. Ravona-Springer R, Davidson M, Noy S. The role of cardiovascular risk factors in Alzheimer's disease. CNS Spectr. 2003 Nov; 8(11):824-33.
    View in: PubMed
    Score: 0.007
  116. Nash IS, Mosca L, Blumenthal RS, Davidson MH, Smith SC, Pasternak RC. Contemporary awareness and understanding of cholesterol as a risk factor: results of an American Heart Association national survey. Arch Intern Med. 2003 Jul 14; 163(13):1597-600.
    View in: PubMed
    Score: 0.007
  117. Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, März W, Reckless JP, Stein EA. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003 Mar 10; 163(5):553-64.
    View in: PubMed
    Score: 0.007
  118. Isaacsohn J, Hunninghake D, Schrott H, Dujovne CA, Knopp R, Weiss SR, Bays H, Crouse JR, Davidson MH, Keilson LM, McKenney J, Korenman SG, Dobs AS, Stein E, Krauss RM, Maccubbin D, Cho M, Plotkin DJ, Mitchel YB. Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia. Clin Cardiol. 2003 Jan; 26(1):18-24.
    View in: PubMed
    Score: 0.007
  119. Adunsky A, Chesnin V, Davidson M, Gerber Y, Alexander K, Haratz D. A cross-sectional study of lipids and ApoC levels in Alzheimer's patients with and without cardiovascular disease. J Gerontol A Biol Sci Med Sci. 2002 Nov; 57(11):M757-61.
    View in: PubMed
    Score: 0.007
  120. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002 Jul 03; 288(1):49-57.
    View in: PubMed
    Score: 0.007
  121. Meltzer HY, Davidson M, Glassman AH, Vieweg WV. Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. J Clin Psychiatry. 2002; 63 Suppl 9:25-9.
    View in: PubMed
    Score: 0.007
  122. Siscovick D, Alexander R, Davidson M, Leinonen M, O'Connor S, Ewald P, Meier C, Puolakkainen M, Hughes J, Nieto J. Collaborative multidisciplinary workshop report: the role of epidemiology studies in determining a possible relationship between Chlamydia pneumoniae infection and atherothrombotic diseases. J Infect Dis. 2000 Jun; 181 Suppl 3:S430-1.
    View in: PubMed
    Score: 0.006
  123. Maki KC, Davidson MH, Marx P, Cyrowski MS, Maki A. Association between elevated plasma fibrinogen and the small, dense low-density lipoprotein phenotype among postmenopausal women. Am J Cardiol. 2000 Feb 15; 85(4):451-6.
    View in: PubMed
    Score: 0.006
  124. Maki KC, Davidson MH, Cyrowski MS, Maki AC, Marx P. Low-density lipoprotein subclass distribution pattern and adiposity-associated dyslipidemia in postmenopausal women. J Am Coll Nutr. 2000 Feb; 19(1):23-30.
    View in: PubMed
    Score: 0.006
  125. Harvey PD, Silverman JM, Mohs RC, Parrella M, White L, Powchik P, Davidson M, Davis KL. Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients. Biol Psychiatry. 1999 Jan 01; 45(1):32-40.
    View in: PubMed
    Score: 0.005
  126. Maki KC, Davidson MH, McDonald A, Malik KC. Fiber intake and risk of developing non-insulin-dependent diabetes mellitus. JAMA. 1997 Jun 11; 277(22):1761; author reply 1762.
    View in: PubMed
    Score: 0.005
  127. Ussery XT, Gessner BD, Lipman H, Elliott JA, Crain MJ, Tien PC, Parkinson AJ, Davidson M, Facklam RR, Breiman RF. Risk factors for nasopharyngeal carriage of resistant Streptococcus pneumoniae and detection of a multiply resistant clone among children living in the Yukon-Kuskokwim Delta region of Alaska. Pediatr Infect Dis J. 1996 Nov; 15(11):986-92.
    View in: PubMed
    Score: 0.005
  128. Ashraf T, Hay JW, Pitt B, Wittels E, Crouse J, Davidson M, Furberg CD, Radican L. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol. 1996 Aug 15; 78(4):409-14.
    View in: PubMed
    Score: 0.005
  129. Harvey PD, Putnam KM, Davidson M, Kahn RS, Powchik P, McQueeney R, Keefe RS, Davis KL. Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients. Psychiatry Res. 1991 Sep; 38(3):285-92.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.